{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T21:06:28Z","timestamp":1770325588000,"version":"3.49.0"},"reference-count":18,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2021,2,1]]},"DOI":"10.1001\/jamainternmed.2020.5921","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T16:02:06Z","timestamp":1604937726000},"page":"162","source":"Crossref","is-referenced-by-count":33,"title":["Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018"],"prefix":"10.1001","volume":"181","author":[{"given":"Patrick C.","family":"DeMartino","sequence":"first","affiliation":[{"name":"Division of Pediatric Hematology and Oncology, Oregon Health & Science University, Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milo\u0161 D.","family":"Miljkovic","sequence":"additional","affiliation":[{"name":"Medical Oncology Service, National Cancer Institute, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Epidemiology & Biostatistics, Department of Medicine, University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"2","key":"ioi200083r3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010-2020.","volume":"103","author":"Mariotto","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"ioi200083r5","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1001\/jamaoncol.2015.0373","article-title":"Five years of cancer drug approvals: innovation, efficacy, and costs.","volume":"1","author":"Mailankody","year":"2015","journal-title":"JAMA Oncol"},{"issue":"7","key":"ioi200083r6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41571-018-0030-2","article-title":"Low-value approvals and high prices might incentivize ineffective drug development.","volume":"15","author":"Prasad","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"ioi200083r7","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamainternmed.2017.3601","article-title":"Research and development spending to bring a single cancer drug to market and revenues after approval.","volume":"177","author":"Prasad","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"8","key":"ioi200083r9","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jamaoncol.2018.1660","article-title":"Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology.","volume":"4","author":"Marquart","year":"2018","journal-title":"JAMA Oncol"},{"issue":"5","key":"ioi200083r10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs.","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"3","key":"ioi200083r11","doi-asserted-by":"publisher","first-page":"e200423","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs.","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"5","key":"ioi200083r12","doi-asserted-by":"publisher","first-page":"v924","DOI":"10.1093\/annonc\/mdz394.086","article-title":"Clinical benefit and prices of cancer drugs in the US and Europe.","volume":"30","author":"Vokinger","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"ioi200083r15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1200\/JCO.2016.72.2124","article-title":"Trajectories of injectable cancer drug costs after launch in the United States.","volume":"36","author":"Gordon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"ioi200083r16","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamainternmed.2019.0462","article-title":"Assessment of the clinical benefit of cancer drugs receiving accelerated approval.","volume":"179","author":"Gyawali","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"15","key":"ioi200083r17","doi-asserted-by":"publisher","first-page":"6651","DOI":"10.1002\/cam4.v8.15","article-title":"Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health Administration.","volume":"8","author":"Aspinall","year":"2019","journal-title":"Cancer Med"},{"issue":"11","key":"ioi200083r18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","article-title":"Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting.","volume":"8","author":"Richardson","year":"2018","journal-title":"Blood Cancer J"},{"key":"ioi200083r1","unstructured":"Global oncology trends 2018. IQVIA Institute for Human Data Science. May 24, 2018. Accessed September 30, 2019. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports\/global-oncology-trends-2018"},{"key":"ioi200083r2","unstructured":"National health expenditure projections 2018-2027. Centers for Medicare & Medicaid Services. Updated December 17, 2019. Accessed January 13, 2020. https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/NationalHealthExpendData\/Downloads\/ForecastSummary.pdf"},{"key":"ioi200083r4","unstructured":"Spending on cancer meds in the U.S. doubled from 2012-2017\u2014expected to double again by 2022 to $100 billion. News release. IQVIA Institute for Human Data Science. May 24, 2018. Accessed December 31, 2019. https:\/\/www.iqvia.com\/newsroom\/2018\/05\/iqvia-institute-for-human-data-science-study-spending-on-cancer-meds-in-the-us-doubled-from-2012-201"},{"key":"ioi200083r8","unstructured":"Silverman? E. Colorado is the latest state to be sued for restricting access to hepatitis C drugs. STAT News. September 22, 2016. Accessed December 31, 2019. https:\/\/www.statnews.com\/pharmalot\/2016\/09\/22\/colorado-sued-for-restricting-hepatitis-c-medicine\/"},{"key":"ioi200083r13","unstructured":"National health expenditure fact sheet. Centers for Medicare & Medicaid Services. Accessed December 31, 2019. https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/NationalHealthExpendData\/NHE-Fact-Sheet"},{"key":"ioi200083r14","unstructured":"Guzman? G. New data show income increased in 14 states and 10 of the largest metros. United States Census Bureau. September 26, 2019. Accessed November 1, 2019. https:\/\/www.census.gov\/library\/stories\/2019\/09\/us-median-household-income-up-in-2018-from-2017.html"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2772334\/jamainternal_demartino_2020_oi_200083_1611344088.38278.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T06:00:25Z","timestamp":1612245625000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2772334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2020.5921","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,1]]}}}